Richard Andraws, MD
Cardiovascular Disease · South Plainfield, NJNPI 1649447269
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $490 and has fallen 86.9% since, to $64 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 46 payments — averaging $27.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$277
- Abbott$272
- Johnson & Johnson$255
- Pfizer$188
- Boehringer Ingelheim$57
- Novartis$50
- plus $182 from 10 others
What the payments were for
- Food & beverage$1,282100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $277 |
| Abbott | 2 | $272 |
| Johnson & Johnson | 10 | $255 |
| Pfizer | 8 | $188 |
| Boehringer Ingelheim | 4 | $57 |
| Novartis | 3 | $50 |
| Baxter Healthcare | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $17 |
| Biotronik Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $12 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quadra Assura CRT Defibrillator$180
- SelectSecure$142
- XARELTO$116
- VYNDAQEL$113
How this compares
$1,282 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 414 | $485,100 |
| EntrestoSacubitril/Valsartan | 88 | $110,428 |
| XareltoRivaroxaban | 89 | $77,560 |
| MultaqDronedarone Hcl | 34 | $58,438 |
| JardianceEmpagliflozin | 42 | $39,897 |
| FarxigaDapagliflozin Propanediol | 28 | $37,485 |
| Repatha SureclickEvolocumab | 32 | $22,992 |
| BrilintaTicagrelor | 12 | $10,377 |
| Rosuvastatin Calcium | 366 | $6,218 |
| Metoprolol Succinate | 336 | $5,763 |
| Nebivolol Hcl | 83 | $5,448 |
| PradaxaDabigatran Etexilate Mesylate | 13 | $5,330 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 96 | $5,209 |
| Icosapent Ethyl | 15 | $4,761 |
| Ranolazine ErRanolazine | 31 | $4,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $188 | $485,100414 claims |
| NovartisEntresto | $50 | $110,42888 claims |
| Johnson & JohnsonXarelto | $255 | $77,56089 claims |
| Boehringer IngelheimJardiance, Pradaxa | $57 | $45,22755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in South Plainfield
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.